Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases
نویسندگان
چکیده
منابع مشابه
Rare diseases and orphan drugs.
According to the Regulation (EC) N. 141/2000 of the European Parliament and of the Council, rare diseases are life-threatening or chronically debilitating conditions, affecting no more than 5 in 10 000 persons in the European Community. It is estimated that between 6000 to 8000 distinct rare diseases affect up to 6% of the total EU population. Therefore, these conditions can be considered rare ...
متن کامل[The pharmacist, rare diseases and orphan medicines].
Treatment of rare diseases is often complicated due to the difficulties posed by the research and development of medicines by the pharmacological industry. One of the greatest concerns of this group of patients, which is both scarce and diverse, is access to available medicines. The European Medicine Agency establishes the term orphan medicines and the incentives and bases for their commerciali...
متن کاملEthnobotanical Study of Medicinal Plants used in Skin Diseases in the Area Alamut-Qazvin, Iran
Background: Medicinal plants have been used for treatment of diseases and finding of new drugs. Botanical valuable traditional methods, offer finding new medicinal plants and herbal medicines. Objective: The aim of this study was the identification of important medicinal plants that widely were used by local inhabitants, in the treatment of skin diseases in the area of Alamut-Qazvin, Iran. M...
متن کاملGlobal effort against rare and orphan diseases.
T he fifth International Congress on Rare Pulmonary Diseases and Orphan Drugs will take place in Milan, Italy, on February 8–9, 2013 (www.pulmonaryrarediseases. com). 10 yrs have passed since the first Congress was held. Since then, the Congress has taken place regularly every 2 yrs, with growing success and ever increasing numbers of participants and speakers from around the world. The Interna...
متن کاملRare diseases and orphan drugs: Latvian story
BACKGROUND Ten years have passed since Latvia became a Member State of the EU in 2004. As a result European regulations, including those related to rare diseases and orphan drugs, have been applied to Latvian legislative system. Orphan diseases have been recognized as a priority area for action in the public health system, though there are significant differences in the national healthcare serv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Discovery Today
سال: 2020
ISSN: 1359-6446
DOI: 10.1016/j.drudis.2019.10.015